Deciding which patients with chronic hepatitis B should be treated is not as simple as determining if their ALT and DNA levels fall above guideline thresholds. Here’s my take.
Preventing mother-to-child transmission of HBV infection is critical to ensure the long-term health of the newborn. Here’s how we can prevent infection in infants born to mothers with HBV infection.
The early detection of HCC in patients with chronic HBV infection means the difference between curable vs terminal disease. Here is how I ensure I do not miss HCC in my patients.
What are the pros and cons of discontinuing oral therapy with nucleos(t)ide analogues in patients with chronic HBV infection? Here’s my take.
How do you distinguish between patients who are true inactive carriers and those with immune active HBeAg-negative chronic hepatitis B? Here’s my take.
You are accessing CCO's educational content today as a Guest user.
If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.